Screening

In early August 2023, the Polish Agency for Health Technology Assessment and Tariff System (AOTMiT) announced the start of the evaluation of several technologies in men’s health, neuromodulation and in-vitro diagnostics fields.

In April and May 2023, it was announced that the Galician Agency for Health Technology Assessment (AVALIA-T) initiated several HTAs, including the evaluations in the e-health, nephrology and urology, men’s health, IVD, obstetrics and gynecology, pulmonary and airways, surgical procedures, and some other fields.

On March 17, 2023, the French National Authority for Health (HAS) published an update on its recommendations for techniques to be used within the organized breast cancer screening. HAS recommends introducing mammography by tomosynthesis in association with the reconstruction of a synthetic 2D image.

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

On February 23, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to preventing the family risk of colorectal carcinoma, shared decision-making in the hospitals, and digitally supported drug therapy management.

In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields.

On January 24, 2023, the Swedish National Board of Health and Welfare recommended introducing a national screening program for spinal muscular atrophy (SMA) in newborns. It will identify children with a homozygous deletion in the SMN1 gene and 1–3 copies of the SMN2 gene. SMA testing must be included in the existing newborn screening (so-called PKU test). The launch of the new screening program is expected in the summer of 2023.

On December 19, 2022, the Dutch Healthcare Authority (NZa) issued a draft release of the DRG package for 2024, including new procedure codes, new diagnosis codes, and several new DRGs. These changes concern pulmonary, gynecology, ENT, orthopedics, and other technology groups.

On December 16, 2022, a decision of the National Union of Health Insurance Funds (UNCAM) relating to the update of the NABM Nomenclature for IVD tests was published in the Official Journal of the French Republic. Various changes were introduced, including the inclusion of new codes, modifications of the existing ones, and tariff changes.

On December 1, 2022, the Swiss Federal Office of Public Health published the changes that will occur to the Services Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The updates will enter into force on January 1, 2023, and they relate to the list of explicitly evaluated services (Annex 1 of KLV/OPre), outpatient-before-hospital services (Annex 1a), List of Tools and Appliances(Annex 2), and List of Analyses (Annex 3).

On November 17, 2022, the Ministry of Health and Prevention published the Order in the Official Journal of the French Republic on the extension of the national newborn screening by laboratory diagnostics to seven more diseases (inborn errors of metabolism).

On October 19, 2022, it was announced by the Ministry of Health that the 2023 General State Budget in the field of health would comprise €2,746.17 million, which is €199.32 million (7.83%) more than in 2022. The aim is to strengthen the National Health System (SNS) and achieve a more robust, more equitable, and more modern system capable of adapting to the population's health needs.